The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving malaria elimination from the Asia–Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimination Network Vivax Working Group in October 2016, a round table discussion was held to discuss the programmatic issues hindering the widespread use of primaquine (PQ) radical cure. Participants included 73 representatives from 16 partner countries and 33 institutional partners and other research institutes. In this meeting report, the key discussion points are presented and grouped into five themes: (i) current barriers for glucose-6-phosphate deficiency (G6PD) testing prior to PQ radical cure, (ii) necessary properties of G6PD tests for wide scale deployment, (iii) the promotion of G6PD testing, (iv) improving adherence to PQ regimens and (v) the challenges for future tafenoquine (TQ) roll out. Robust point of care (PoC) G6PD tests are needed, which are suitable and cost-effective for clinical settings with limited infrastructure. An affordable and competitive test price is needed, accompanied by sustainable funding for the product with appropriate training of healthcare staff, and robust quality control and assurance processes. In the absence of quantitative PoC G6PD tests, G6PD status can be gauged with qualitative diagnostics, however none of the available tests is currently sensitive enough to guide TQ treatment. TQ introduction will require overcoming additional challenges including the management of severely and intermediately G6PD deficient individuals. Robust strategies are needed to ensure that effective treatment practices can be deployed widely, and these should ensure that the caveats are outweighed by the benefits of radical cure for both the patients and the community. Widespread access to quality controlled G6PD testing will be critical.
Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti Elyazar I, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg. 2007;77:984–91. PubMed
RBM. The Asia Pacific Malaria Elimination Network (APMEN) supporting the common goal of a malaria-free Asia Pacific (Progress & impact series, 11). Geneva: Roll Back Malaria Parternship Secreteriat; 2014.
von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112. CrossRef
WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
WHO. World Malaria Report 2016. Geneva: World Health Organization; 2016. http://www.who.int/malaria/publications/world-malaria-report-2016/report/en/.
Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Perceptions of P. vivax malaria and barriers to routine G6PD testing prior to its treatment with primaquine. Malar J. 2017. (under review).
Vivax Working Group. Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group. Malar J. 2015;14:484. CrossRef
Recht J, Ashley E, White NJ. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization; 2014.
Beutler E, Duparc S. G6PD deficiency working group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779–89. PubMed
IMPROV Study Group. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infect Dis. 2015;15:558. CrossRef
Devine A, Parmiter M, Chu C, Bancone G, Nosten F, Price RN et al. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: a cost-effectiveness analysis. PLoS Neglect Trop Dis. Under review. 2017.
Skarbinski J, Ouma PO, Causer LM, Kariuki SK, Barnwell JW, Alaii JA, et al. Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether–lumefantrine in Kenya: a cluster randomized trial. Am J Trop Med Hyg. 2009;80:919–26. PubMed
Malaria Consortium. Learning Brief-Successful roll out of RDTs in Uganda.
Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049–58. CrossRefPubMed
Espino FE, Bibit JA, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of three screening test kits for G6PD enzyme deficiency: implications for its use in the radical cure of vivax malaria in remote and resource-poor areas in the Philippines. PLoS ONE. 2016;11:e0148172. CrossRefPubMedPubMedCentral
Henriques G, Raut S, Phommasone K, Adhikari B, Pongvongsa T, Ley B, et al. Prevalence of glucose-6-phosphote dehydrogenase deficiency among a rural and remote population of Lao PDR (Laos). Atlanta: ASTMH Annual Meeting; 2016.
Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW. Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res. 2015;165:677–88. CrossRefPubMedPubMedCentral
Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, et al. Assessment of point-of-care diagnostics for G6PD deficiency in malaria endemic rural eastern Indonesia. PLoS Neglect Trop Dis. 2016;10:e0004457. CrossRef
Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, Yimsamran S, Thanyavanich N, Wuthisen P, et al. Directly observed therapy with primaquine to reduce the recurrence rate of Plasmodium vivax infection along the Thai-Myanmar border. Southeast Asian J Trop Med Public Health. 2011;42:9–18. PubMed
CNM. Meeting report. Meeting on Diagnosis and Treatment in the context of elimination. Phnom Penh: CNM2016.
WHO. World Malaria Report. Geneva. Switzerland: World Health Organization; 2015. p. 2015.
- Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group
Mohammad Shafiul Alam
Ayodhia P. Pasaribu
Gonzalo J. Domingo
Mohammad M. Aktaruzzaman
Surender Nath Sharma
Rose Nanti Binti Mudin
Garib Da Thakur
Leo Sora Makita
Manjula N. Danansuriya
Santha D. Mudiyanselage
Thang Ngo Duc
Ha Do Manh
Young S. Hong
Jack S. Richards
Xavier C. Ding
Wasif Ali Khan
Ching Swe Phru
Rosalind E. Howes
Ipsita Pal Bhowmick
Carol H. Sibley
Lorenz von Seidlein
J. Kevin Baird
Ric N. Price
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II